Verrica Pharmaceuticals, the dermatology company headquartered at 44 West Gay Street in downtown West Chester, will release its second-quarter 2026 financial results Thursday, Aug. 6, giving investors and local watchers a first look at the company's performance since it signed an international licensing deal and advanced a new clinical trial.
The company will host a conference call and webcast at 4:30 p.m. Thursday to discuss results for the quarter ended June 30, according to a Globe Newswire release issued July 30.
Analysts expect Verrica (Nasdaq: VRCA) to report roughly $5.73 million in quarterly revenue and earnings per share of negative $0.41, according to MarketBeat consensus estimates. In Q1 2026, the company beat expectations with $5.02 million in revenue, topping the $4.51 million estimate.
Verrica employs 76 full-time workers and trades at a market capitalization of roughly $89 million to $93 million. Its stock has ranged between $3.28 and $9.82 over the past 52 weeks.
YCANTH momentum heading into the call
The earnings call is the first since Verrica dosed the first U.S. patient in COVE-3, its second pivotal Phase 3 trial testing YCANTH for common warts. The company describes common warts as the largest remaining unmet need in medical dermatology.
It's also the first quarterly report since Verrica signed an exclusive licensing deal with Israel's Medomie Pharma on July 21, giving Medomie rights to commercialize YCANTH in Israel. Verrica will receive 60% of net selling prices and is eligible for up to $8.2 million in milestone payments under that agreement.
In full-year 2025, YCANTH net revenue grew 130% to $15.3 million, and dispensed applicator units nearly doubled to 51,296, according to the company's annual earnings release. Total company revenue hit $35.6 million, up from $7.6 million in 2024, while selling and administrative expenses fell more than 40% to $35.2 million.
CEO Jayson Rieger said in that March 11 earnings release that the company's strategy "allowed us to nearly double dispensed applicator units of YCANTH from the prior year while cutting selling, general and administrative expenses by over 40% over that same period."
Pipeline and international expansion
Beyond molluscum contagiosum, Verrica is developing VP-315 (ruxotemitide) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma, licensed worldwide from Lytix Biopharma. The company was advancing toward pivotal Phase 3 studies as of early 2026.
Internationally, Verrica's Japanese partner Torii Pharmaceutical has already launched YCANTH in Japan, and the company has gained alignment with the European Medicines Agency on a regulatory pathway that would not require additional clinical studies.
How to listen
The public can access Thursday's call via webcast at verrica.com or by phone at 1-800-225-9448 (domestic) or 1-203-518-9708 (international), using conference ID: VERRICA. A replay will be archived for 90 days.
